The neurobiological effects of clozapine are under characterised. We examined the effects clozapine treatment on subcortical volume and cortical thickness and investigated whether macrostructural changes were linked to alterations in glutamate or N-acetylaspartate (NAA). Data were acquired in 24 patients with treatment-resistant schizophrenia before and 12 weeks after switching to clozapine. During clozapine treatment we observed reductions in caudate and putamen volume, lateral ventricle enlargement (P < 0.001), and reductions in thickness of the left inferior temporal cortex, left caudal middle frontal cortex, and the right temporal pole. Reductions in right caudate volume were associated with local reductions in NAA (P = 0.002). None of the morphometric changes were associated with changes in glutamate levels. These results indicate that clozapine treatment is associated with subcortical volume loss and cortical thinning and that at least some of these effects are linked to changes in neuronal or metabolic integrity.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891256 | PMC |
| http://dx.doi.org/10.1038/s41537-022-00230-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Response to the Letter to the Editor "Reflections on a study of electroconvulsive therapy for clozapine-refractory schizophrenia" (Jolly et al. Schizophrenia Research, 267 (2024) 32-33).
Schizophr Res
January 2025
Department and Institute of Psychiatry-University of São Paulo Medical School (FMUSP), Brazil.
Lateral Occipital Cortex as a Novel Target for Neuromodulation to Attenuate Auditory and Visual Hallucinations in a Patient with Ultra-treatment-resistant Schizophrenia: A Case Report.
Clin Psychopharmacol Neurosci
February 2025
Department of Psychiatry, National Institute of Mental Health and Neuro Sciences (NIMHANS), Bengaluru, India.
Auditory/visual hallucinations and perceptual anomalies are one of the core symptoms experienced by patients with schizophrenia. Studies have implicated lateral occipital cortex (LOC) as one of the areas to be aberrantly functioning in schizophrenia, possibly associated with the auditory/visual symptoms of schizophrenia. Here we report of a case of a 29-year-old female diagnosed with treatment resistant schizophrenia on clozapine with persistent auditory verbal hallucinations (AVH) and visual anomalies.
View Article and Find Full Text PDFWhat is the current scope of research assessing patients' and clinicians' perspectives on clozapine treatment? A comprehensive scoping review.
BMJ Open
January 2025
Psychiatric Services Region Zealand East, Roskilde, Denmark.
Objectives: Clozapine is continuously underused. The existing systematic reviews addressing barriers to clozapine prescribing primarily focus on clinical staff's attitudes and perceived barriers to prescribing. However, a preliminary literature search revealed additional literature on the subject not previously included in systematic reviews, including literature on patient perspectives.
View Article and Find Full Text PDFSchizophrenia and Bone Marrow Disorders: An Emerging Clinical Association.
Cureus
December 2024
Department of Psychiatry, Texas Tech University Health Sciences Center, Odessa, USA.
Schizophrenia is a chronic psychiatric disorder with a complex etiology involving genetic, neurobiological, and environmental factors. Many individuals with schizophrenia experience treatment resistance despite advances in pharmacologic and non-pharmacologic interventions. Immune dysregulation, characterized by altered cytokine levels, immune-related gene expression, and neuroinflammation, plays a critical role in schizophrenia's pathogenesis.
View Article and Find Full Text PDFClinical and Demographic Predictors of Early Clozapine Discontinuation Across Mood and Psychotic Disorders.
J Clin Psychopharmacol
January 2025
Department of Pharmacy, Mayo Clinic, Rochester, MN.
Background: Clozapine is effective for treatment-resistant schizophrenia and bipolar disorder but is often discontinued due to adverse effects. This study compared early clozapine discontinuation rates and reasons in patients with mood and psychotic disorders.
Methods: Data from all individuals with mood or psychotic disorders who initiated clozapine for the first time at the inpatient psychiatric unit of Mayo Clinic, Rochester, Minnesota, between 2014 and 2022 were retrospectively analyzed.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!